Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic drugs (e.g., gabapentin, pregabalin), antidepressants (e.g., amitriptyline, duloxetine), and dual-acting opioid analgesics (e.g., tramadol), as well as topical lidocaine (e.g., Scilex’s ZTlido) and topical capsaicin (e.g., Averitas’s Qutenza), However, current analgesics fall short in providing adequate relief due to side effects, prolonged titration, inadequate dosing, poor compliance, and low treatment satisfaction. Thus, unmet need and opportunity exist for new options, particularly those with novel mechanisms of action. The successful launch of a novel analgesic for PHN or other forms of neuropathic pain will require a granular understanding of treatment patterns in PHN, a common gateway market for emerging neuropathic pain drugs.
Questions answered
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboards featuring interactive visuals, easy navigation, and expanded analyses
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Collegium Pharmaceuticals, BioDelivery Sciences International, Averitas, Scilex, Kowa Pharmaceuticals, Azurity Pharmaceuticals, Almatica
Key drugs: Gabapentin, pregabalin, Qutenza, ZTlido, Gralise, Horizant, amitriptyline, duloxetine, venlafaxine, milnacipran, topiramate, NSAIDs, opioids, tramadol, tapentadol
Key analysis provided